Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
AstraZeneca – Discontinuation of Lumoxiti® (moxetumomab pasudotox-tdfk)
January 10, 2023 - AstraZeneca announced plans to permanently discontinue Lumoxiti (moxetumomab pasudotox-tdfk) from the U.S. market by August 31, 2023.
